AMX0035 and Progressive Supranuclear Palsy
Purpose
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.
Conditions
- Progressive Supranuclear Palsy
- PSP
- Neurodegenerative Diseases
- Atypical Parkinsonism
Eligibility
- Eligible Ages
- Between 40 Years and 80 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male or female 40 to 80 years of age, inclusive - Diagnosis of possible or probable PSP Richardson Syndrome - Presence of PSP symptoms for <5 years - Score of <40 on the total (28-item) Progressive Supranuclear Palsy Rating Scale (PSPRS) - Able to walk independently or with minimal assistance - Minimum score of 24 on the Mini Mental State Examination (MMSE) - Must reside outside a skilled nursing facility or dementia care facility at the time of screening. Residence in an assisted living facility is allowed - Must have a study partner willing to attend study visits and provide information on participant's status - Capable of providing informed consent - Capable and willing to comply with trial procedures including visits to the trial clinic, visit requirements and treatment schedule, including MRI scans - Female participants of childbearing potential must agree to use effective birth control for the duration of the study and for 6 months after last dose of study drug. - Males must agree to use effective birth control method for the duration of the study and for 6 months after the last dose of study drug. Men must not plan to donate sperm.
Exclusion Criteria
- Require use of a feeding tube - Evidence of any neurological disorder that could explain signs of PSP - Evidence of any clinically significant neurological disorder other than PSP, including significant cerebrovascular abnormalities, vascular dementia, motor neuron disease or ALS, Huntington's disease, normal pressure hydrocephalus, brain tumor, seizure disorder, multiple sclerosis, or known structural brain abnormalities. - History of autosomal dominant PSP due to a Microtubule Associated Protein Tau (MAPT) mutation - History of an autosomal dominant mutation associated with Frontotemporal Lobar Degeneration (FTLD) - Prior or current diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder - Presence of unstable psychiatric disease, cognitive impairment (e.g., major cognitive dysfunction), dementia, major depression, or substance abuse that would impair ability of the participant to provide informed consent and follow instructions - Abnormal liver function - Renal insufficiency - Ongoing anemia - History of Class III/IV heart failure per New York Heart Association (NYHA)
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Intervention Model Description
- A35-009 (ORION) is a blinded, randomized, placebo-controlled, two-part Phase 2b/3 study, each part consisting of a 52-week double-blind, placebo-controlled phase followed by an optional 52-week open-label extension phase.
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Masking Description
- Participants, Care providers, Investigators, and study staff will be blinded to participant group assignment during the double-blind phase and extension phase
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental AMX0035 |
AMX0035 administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study For participants electing to continue into the open-label phase at Week 52; AMX0035 will be administered once daily for first 2 weeks and then twice daily for remainder of open-label phase |
|
|
Placebo Comparator Placebo |
Placebo administered by mouth for 52 weeks: once daily for first 2 weeks and then twice daily for remainder of study |
|
Recruiting Locations
Mayo Clinic
Scottsdale, Arizona 85259
Scottsdale, Arizona 85259
University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
Parkinson's & Movement Disorder Institute
Fountain Valley, California 92708
Fountain Valley, California 92708
University of California, San Francisco (UCSF)
San Francisco, California 94158
San Francisco, California 94158
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida 33486
Boca Raton, Florida 33486
Mayo Clinic Florida
Jacksonville, Florida 32224
Jacksonville, Florida 32224
Northwestern University PD and Movement Disorders Center
Chicago, Illinois 60611
Chicago, Illinois 60611
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas 66160
Kansas City, Kansas 66160
University of Kentucky Medical Center
Lexington, Kentucky 40536-0274
Lexington, Kentucky 40536-0274
Ochsner Medical Center
New Orleans, Louisiana 70121
New Orleans, Louisiana 70121
Massachusetts General Hospital
Boston, Massachusetts 02114
Boston, Massachusetts 02114
Quest Research Institute
Farmington Hills, Michigan 48334
Farmington Hills, Michigan 48334
Mayo Clinic - Rochester
Rochester, Missouri 55905
Rochester, Missouri 55905
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada 89106
Las Vegas, Nevada 89106
The Cleveland Clinic Foundation
Cleveland, Ohio 44195
Cleveland, Ohio 44195
Oregon Health & Science University
Portland, Oregon 97239
Portland, Oregon 97239
Pennsylvania Hospital
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19107
Medical University of South Carolina (MUSC)
Charleston, South Carolina 29425
Charleston, South Carolina 29425
Veracity Neuroscience, LLC
Memphis, Tennessee 38157
Memphis, Tennessee 38157
Vanderbilt University Medical Center
Nashville, Tennessee 37232
Nashville, Tennessee 37232
Baylor College of Medicine
Houston, Texas 77030
Houston, Texas 77030
Central Texas Neurology Consultants
Round Rock, Texas 78681
Round Rock, Texas 78681
Virginia Commonwealth University Department of Neurology
Richmond, Virginia 23298-0059
Richmond, Virginia 23298-0059
More Details
- NCT ID
- NCT06122662
- Status
- Recruiting
- Sponsor
- Amylyx Pharmaceuticals Inc.
Detailed Description
AMX0035 is a fixed dose combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the endoplasmic reticulum (ER) and mitochondria. This clinical trial is designed to demonstrate that AMX0035 is safe and tolerable, and to assess its effect on disease progression as measured by the Progressive Supranuclear Palsy (PSP) Rating Scale (PSPRS) over a 52-week double-blind phase. The Phase 2b and Phase 3 study portions are planned to feature an identical design: a randomized, double-blind, placebo-controlled phase that is followed by an optional open-label extension (OLE) phase. The phase 3 portion of ORION may be initiated based on results of the phase 2b Interim Analysis and/or the Primary Analysis and the totality of data from the Phase 2b study portion.